Familial Adenomatous Polyposis and MUTYH-Associated Polyposis

Familial adenomatous polyposis (FAP) is caused by pathogenic variants in the APC gene resulting in the development of hundreds to thousands of adenomatous colonic polyps beginning in early adolescence. The lifetime risk for cancer in individuals with FAP is 100 percent. Additional symptoms may include dental anomalies, polyps of the gastric fundus and duodenum, and congenital hypertrophy of the retinal pigment epithelium (CHRPE). Pathogenic APC variants may also cause other related syndromes, including attenuated FAP (AFAP), gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS), Gardner syndrome, and Turcot syndrome.

MUTYH-associated polyposis (MAP), caused by biallelic pathogenic variants in the MUTYH gene, can result in the development of colon polyps that are less numerous (typically 10-100) and is often diagnosed later in life. Genetic testing may be used to assess individuals at risk for FAP, other APC-associated polyposis, or MAP due to a suggestive personal or family history.

Disease Overview

Incidence/Prevalence
- Colorectal cancer (CRC): ~140,000/year in U.S.
  - Lifetime risk of developing CRC: 6%
  - Majority of CRC is not hereditary or inherited
  - FAP and MAP each account for <1% of CRC cases
- ~1% of Caucasians are predicted to carry a single pathogenic MUTYH variant

Age of Onset
- FAP: early adolescence
- MAP: third decade of life or later

Symptoms

FAP
- Development of hundreds to thousands of adenomatous colonic polyps
- Dental anomalies
- Polyps of gastric fundus and duodenum
- Congenital hypertrophy of retinal pigment epithelium (CHRPE)

Related Tests

Tests to Consider

Familial Adenomatous Polyposis Panel: (APC) Sequencing and Deletion/Duplication, (MUTYH) 2 Mutations 2004915
Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification
Preferred diagnostic or predictive test for FAP and MAP

Familial Adenomatous Polyposis (APC) Sequencing 2004863
Method: Polymerase Chain Reaction/Sequencing
- Acceptable diagnostic or predictive test for FAP
- For classic FAP, consider APC sequencing and deletion/duplication testing

MUTYH-Associated Polyposis (MUTYH) Sequencing 2006191
Method: Polymerase Chain Reaction/Sequencing
Diagnostic or predictive test for MAP

Hereditary Gastrointestinal Cancer Panel, Sequencing and Deletion/Duplication 2013449
Method: Massively Parallel Sequencing/Exonic Oligonucleotide-based CGH Microarray/Sequencing/Multiplex Ligation-dependent Probe Amplification
Recommended test to confirm a diagnosis of hereditary gastrointestinal (GI) cancer in individuals with a personal or family history of GI cancer and/or polyposis

Familial Mutation, Targeted Sequencing 2001961
Method: Polymerase Chain Reaction/Sequencing
• Begins generally during early adolescence
• Overall age range of 7-36 years
• Without a preventive colectomy, all individuals with FAP will develop colon cancer during their lifetime
• Mean age at time of diagnosis is 39 years

AFAP

Differs from FAP:
• Typically fewer polyps; 10-100, with an average of 30
• More proximally located polyps
• Cancer generally occurs at a later age

Gardner Syndrome

• Occurs in 20% of families with classic FAP
• Associated with
  ○ Benign osteomas
  ○ Desmoid tumors
  ○ Soft-tissue tumors

Turcot Syndrome

• Colon polyps
• Central nervous system tumors
• Associated with medulloblastoma
• Often caused by pathogenic variants in APC gene
• Turcot with glioblastoma multiforme is usually caused by pathogenic variants in a mismatch repair gene

GAPPS

• Associated with pathogenic variants in promoter 1B of the APC gene
• Fundic gland polyposis
• Increased risk for gastric cancer

MAP

• 10-100 polyps
• ~20-30% of patients with 10-100 polyps have biallelic pathogenic MUTYH variants
• Age of onset is third decade or later

Genetics

Genes

APC, MUTYH

Inheritance

• APC is autosomal dominant
• MUTYH is autosomal recessive

Penetrance
• Classic FAP: 100% in untreated individuals
• Individuals with MAP and colorectal cancer
  - 20% by age 50
  - 43% by age 60

De novo Variants

*APC*: 25% of cases

Test Interpretation

Sensitivity/Specificity

Analytical sensitivity/specificity: 99% for *APC* and *MUTYH*

Clinical Sensitivity

• Classic FAP: ~95%
  - ~90% of pathogenic variants detected by sequencing
  - ~8-12% of pathogenic variants detected by deletion/duplication testing
• Attenuated FAP: <30%
• GAPPS: unknown
• MAP
  - 85% of pathogenic *MUTYH* variants in Northern European Caucasians detected by the 2 pathogenic variants test (Y165C and G382D)
  - 98% of pathogenic *MUTYH* variants detected by full gene sequencing

Results

Positive

• Identification of a single pathogenic variant in *APC* gene
  - Predictive of FAP or *APC*-associated polyposis
• Detection of two pathogenic *MUTYH* variants on opposite chromosomes
  - Predictive of MAP
• Identification of a single pathogenic *MUTYH* variant
  - Individual is a carrier of MAP
  - Individual could be affected if another unidentified pathogenic *MUTYH* variant is present on the opposite chromosome
  - Possible increased risk for cancer has been associated but is not well defined

Negative

• No pathogenic variants were detected in *APC* or *MUTYH* genes
• Does not rule out FAP, *APC*-associated polyposis, or MAP

Inconclusive

• Variant(s) of unknown clinical significance may be detected

Limitations
Diagnostic errors can occur due to rare sequence variations

**APC Gene**
- Deep intronic or regulatory region variants will not be identified
- Breakpoints of large deletions/duplications will not be determined

**MUTYH Gene**
- FAP panel: only two pathogenic MUTYH variants will be tested (Y165C and G382D)
- Not detected on the MUTYH Sequencing test:
  - Large deletions or duplications
  - Deep intronic, regulatory region, or promoter pathogenic variants

References


Related Information

Colorectal Cancer